Alpine Woods Capital Investors’s Minerva Neurosciences NERV Stock Holding History

Alpine Woods Capital Investors’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-7,541	Closed	-$363K	–	264
2020 Q1	$363K	Hold	7,541	–	–	0.08%	192
2019 Q4	$429K	Hold	7,541	–	–	0.08%	191
2019 Q3	$468K	Hold	7,541	–	–	0.09%	175
2019 Q2	$340K	Hold	7,541	–	–	0.07%	216
2019 Q1	$474K	Hold	7,541	–	–	0.1%	179
2018 Q4	$407K	Sell	7,541 -125	-2%	-$9.15K	0.1%	186
2018 Q3	$770K	Buy	7,666 +1,416	+23%	+$106K	0.16%	120
2018 Q2	$413K	Buy	6,250 +3,750	+150%	+$228K	0.09%	161
2018 Q1	$125K	Hold	2,500	–	–	0.01%	386
2017 Q4	$121K	Hold	2,500	–	–	0.01%	431
2017 Q3	$152K	Hold	2,500	–	–	0.01%	434
2017 Q2	$177K	Buy	2,500 +1,250	+100%	+$80.9K	0.01%	423
2017 Q1	$81K	Hold	1,250	–	–	﹤0.01%	447
2016 Q4	$118K	Hold	1,250	–	–	0.01%	435
2016 Q3	$141K	Hold	1,250	–	–	0.01%	406
2016 Q2	$102K	Buy	+1,250	New	+$79.5K	0.01%	404

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alpine Woods Capital Investors's NERV Position: Q2 2020 in Review

Alpine Woods Capital Investors sold out of Minerva Neurosciences (NERV) in Q2 2020, closing a stake of 7,541 shares — an estimated $363K sold.

Alpine Woods Capital Investors first reported a position in NERV in Q2 2016 and held it in 16 quarters. The position peaked at $770K in Q3 2018. 80 funds tracked by Wall St. Rank hold NERV as of Q2 2020.

Alpine Woods Capital Investors reported no remaining Minerva Neurosciences position as of Q2 2020 after selling out during the quarter.
Alpine Woods Capital Investors sold 7,541 Minerva Neurosciences shares in Q2 2020, an estimated $363K.
Alpine Woods Capital Investors first reported a position in Minerva Neurosciences in Q2 2016 and held it in 16 quarters.
Alpine Woods Capital Investors's Minerva Neurosciences position peaked at $770K in Q3 2018.
80 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2020.

Based on Alpine Woods Capital Investors's 13F filing for Q2 2020, filed 10 Aug 2020.